Fused ring compound as STAT6 inhibitor, and preparation method therefor and use thereof
By developing fused-ring compounds as STAT6 inhibitors, the STAT6 pathway is precisely blocked, solving the problem of poor efficacy in treating STAT6-related diseases in existing technologies. Significant therapeutic activity and safety are achieved, expanding its application in oncology.
Patent Information
- Application Number
- PCT/CN2026/081016
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-03-03
- Publication Date
- 2026-11-12
AI Technical Summary
Existing technologies are unable to effectively inhibit the STAT6 signaling pathway, resulting in poor treatment outcomes for various diseases such as inflammatory diseases, autoimmune diseases, and fibrotic diseases, and also lacking safety and widespread applicability.
Develop a fused-ring compound as a STAT6 inhibitor to precisely block the STAT6 pathway for the treatment of STAT6-related diseases. Combined with tumor immunotherapy, it provides significant therapeutic activity and good safety.
This compound has shown significant therapeutic activity and safety in a variety of diseases, expanding the application prospects of oncology and providing new treatment strategies.
Smart Images

Figure PCTCN2026081016-FTAPPB-I100001 
Figure PCTCN2026081016-FTAPPB-I100002 
Figure PCTCN2026081016-FTAPPB-I100003
Abstract
Description
Fused-ring compounds as STAT6 inhibitors, their preparation methods and applications Technical Field
[0001] This invention relates to the field of chemical and pharmaceutical technology, specifically to a fused-ring compound as an inhibitor of the signal transduction and transcriptional activator protein STAT6, its preparation method and application, particularly in the treatment of autoimmune diseases and inflammatory diseases (such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, etc.). Background Technology
[0002] The signal transducer and activator of transcription (STAT) family consists of various transcription factors that play complex and important roles in the regulation of physiological processes such as cell proliferation, differentiation, apoptosis, and angiogenesis. Currently, seven proteins have been identified in the STAT family: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. All genes are located on different chromosomes but share a conserved sequence structure.
[0003] STAT6, a key molecule in the JAK / STAT signaling pathway, plays a crucial role in maintaining pathway operation and gene expression. STAT6 activation is primarily induced by IL-4 and IL-13, and its phosphorylation by JAK kinase at the conserved tyrosine (Y)-641 stimulates target gene transcription. The STAT6-involved signaling pathway is associated with a variety of diseases, including inflammatory diseases (such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease), autoimmune diseases (such as rheumatoid arthritis and systemic lupus erythematosus), tumors (such as solitary fibroma, breast cancer, prostate cancer, melanoma, and malignant lymphoma), and fibrotic diseases (such as pulmonary fibrosis).
[0004] Therefore, STAT6 is an important target for the treatment and drug development of various diseases, and is also a potential intervention target for autoimmune diseases. Developing a new class of highly active STAT6 inhibitors is of great significance and clinical value. Summary of the Invention
[0005] To overcome the shortcomings of existing technologies, this invention provides a fused-ring compound that can be used as a STAT6 inhibitor, its preparation method, and its application. This compound can precisely block the STAT6 pathway and has significant therapeutic activity and good safety in a variety of STAT6-related diseases (such as inflammatory diseases, autoimmune diseases, and fibrotic diseases). It has important clinical translational value and broad application prospects. In addition, it can be combined with tumor immunotherapy to target the STAT6-mediated immunosuppression in the tumor microenvironment, realize a new strategy for tumor treatment, and open up application prospects in the field of oncology.
[0006] In a first aspect of the present invention, a compound or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, or solvate thereof is provided, said compound having the following structure:
[0007] in,
[0008] X1 is selected from: N, CR4;
[0009] X2 is selected from: N, CR5;
[0010] X3 is selected from: N, CR6;
[0011] Y1 is selected from: N, CR7;
[0012] Y2 is selected from: N, CR8;
[0013] Y3 is selected from: N, CR9;
[0014] R4 to R9 are independently selected from: H, D, halogen, cyano, nitro, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 heterocyclic), -OR a -NR a R b -NHC(O)-R a -C(O)NR a R b -C(O)OR a -C(O)-R a -S(O)2-R a -S(O)2-NR a R b ;R a R b Independently selected from: H, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen in the aryl or 4-10 membered heterocyclic group is optionally substituted by one or more groups selected from the following: =O, halogen, cyano, hydroxyl, amino, C1-C 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 alkyl);
[0015] R1 is selected from: 5-6 membered heterocyclic groups, -N(C0-C) 10 Alkyl)C(O)-R 101 -C(O)NR 101 R 102 -P(O)OR 101 OR 102 -CH2P(O)OR 101 OR 102 Among them, R 101 and R 102 Independently selected from: H, D, C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl, -(C0-C6 alkylene)-(C3-C 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10The hydrogen in the aryl or 4-10 membered heterocyclic group is optionally substituted by one or more groups selected from the following: =O, halogen, cyano, hydroxyl, amino, C1-C 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl; the H on the 5-6 membered heterocyclic group is optionally substituted by one or more groups selected from: D, =O, halogen, cyano, hydroxyl, amino, C1-C 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 alkyl);
[0016] Ring A is a 5-7 membered heterocyclic ring;
[0017] R2 is one or more independent substituents on ring A, each R2 being independently selected from: H, D, =O, halogen, cyano, nitro, hydroxyl, amino, C1-C. 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 heterocyclic), -OR 201 -N(C0-C 10 Alkyl)(R 201 -NHC(O)-R 201 -C(O)N(C0-C 10 Alkyl)(R 201 -C(O)OR 201 -C(O)-R 201 -S(O)2-R 201 -S(O)2-N(C0-C 10Alkyl)(R 201 ); R 201 Selected from: H, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen atoms in the aryl or 4-10 membered heterocyclic groups are optionally substituted by one or more groups selected from the following: D, halogen, cyano, hydroxyl, amino, C1-C. 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 alkyl);
[0018] R 10 Selected from: H, D, =O, halogen, cyano, nitro, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 heterocyclic), -OR 1001 -NR 1001 R 1002 -NHC(O)-R 1001 -C(O)NR 1001 R 1002 -C(O)OR 1001 -C(O)-R 1001 -S(O)2-R 1001 -S(O)2-NR1001 R 1002 ;R 1001 R 1002 Independently selected from: H, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen in the aryl or 4-10 membered heterocyclic group is optionally substituted by one or more groups selected from the following: =O, halogen, cyano, hydroxyl, amino, C1-C 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 alkyl);
[0019] Z2 is selected from: N, CR 11 ;R 11 Selected from: H, D, halogen, cyano, nitro, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), wherein the C1-C 10 Alkyl, C3-C 10 The H in the cycloalkyl group is optionally substituted by one or more groups selected from the following: D, halogen, hydroxyl, amino;
[0020] Or, R 10 R 11Together with the atoms to which it is attached, it forms a heterocycle; the H in the heterocycle is optionally substituted by one or more groups selected from: D, =O, halogen, cyano, nitro, hydroxyl, amino, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), wherein the C1-C 10 Alkyl, C3-C 10 The H in the cycloalkyl group is optionally substituted by one or more groups selected from the following: D, halogen, hydroxyl, amino;
[0021] L1 is selected from: -C(O)O-, -C(O)NR L -、-S(O)NR L -、-S(O)2NR L -、-CH2NR L -、-C(O)C(R L1 R L2 -, -OC(O)-, -NR L C(O)-、-NR L S(O)-、-NR L S(O)2-、-NR L CH2-, -C(R) L1 R L2 )C(O)-、-OC(R L1 R L2 )-、-C(R L1 R L2 O-, C2-C4 alkylene, C2-C4 haloalkylene, C2-C4 alkenylene;
[0022] R L R L1 R L2 Independently selected from: H, D, halogens, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl); wherein the C1-C 10 Alkyl, C3-C 10 The H in the cycloalkyl group is optionally substituted by one or more groups selected from the following: D, halogen, hydroxyl, amino; or, R L1 R L2 Together with the carbon atoms they are attached to, they form carbon rings or heterocycles;
[0023] Ring B is C6-C 10 Aromatic rings, 4-12 heterocyclic rings;
[0024] R3 is one or more independent substituents on ring B, each R3 being independently selected from: H, D, halogen, cyano, nitro, hydroxyl, amino, C1-C. 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 heterocyclic), -OR 301 -NR 301 R 302 -NHC(O)-R 301 -C(O)NR 301 R 302 -C(O)OR 301 -C(O)-R 301 -S(O)2-R 301 -S(O)2-NR 301 R 302 ;R 301 R 302 Independently selected from: H, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen atoms in the aryl or 4-10 membered heterocyclic groups are optionally substituted by one or more groups selected from the following: D, halogen, cyano, hydroxyl, amino, C1-C. 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 Alkyl), -C(O)(C1-C 10 alkylene)-O-(C0-C 10 alkyl).
[0025] In some embodiments of the present invention, R 10 R 11 Together with the atoms it is attached to, it forms a heterocycle, and the compound has the following structure:
[0026] Among them, ring E is a 5-6 membered heterocyclic ring;
[0027] R 12 For one or more independent substituents on the E ring, each R 12 Independently selected from: D, =O, halogen, cyano, nitro, hydroxyl, amino, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), wherein the C1-C 10 Alkyl, C3-C 10 The H in the cycloalkyl group is optionally substituted by one or more groups selected from the following: D, halogen, hydroxyl, amino.
[0028] More specifically, the compound has the following structure:
[0029] Z1 is selected from: N, CR 12 .
[0030] More specifically, in Equation II-1, Z1 is N or CH.
[0031] In other embodiments of the invention, R 10 Selected from: H, D, =O, halogen, cyano, nitro, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), wherein the C1-C 10 Alkyl, C3-C 10 The H in the cycloalkyl group is optionally substituted by one or more groups selected from the following: D, halogen, hydroxyl, amino, Z2 is CR 11 More specifically, R 10 It is H or =O.
[0032] Specifically, X1, X2, and X3 are independently selected from: N and CH.
[0033] In some embodiments of the present invention, X1 is CH, X2 is CH, and X3 is CH; in other embodiments of the present invention, X1 is N, X2 is CH, and X3 is CH; in still other embodiments of the present invention, X1 is CH, X2 is N, and X3 is CH.
[0034] Specifically, Y1 and Y3 are independently selected from: N and CH.
[0035] In some embodiments of the present invention, Y1 is CH and Y3 is CH; in other embodiments of the present invention, Y1 is N and Y3 is CH; in still other embodiments of the present invention, Y1 is CH and Y3 is N.
[0036] In some embodiments of the present invention, Y2 is CR8. More specifically, R8 is selected from: H, halogens, C1-C6 alkyl groups, and C1-C6 haloalkyl groups. In some embodiments of the present invention, R8 is selected from: halogens (such as F, Cl), and trifluoromethyl groups.
[0037] In some embodiments of the present invention, the compound has the following structure:
[0038] Specifically, ring A is a 5-, 6-, or 7-membered heterocyclic ring, for example... In some embodiments of the present invention Some have the following structure:
[0039] In some embodiments of the present invention Some have the following structure:
[0040] In some embodiments of the present invention, the compound has the following structure:
[0041] in particular
[0042] In some preferred embodiments of the present invention, the compound has the following structure:
[0043] Specifically, R1 is selected from: -N(C0-C 10 Alkyl)C(O)-R 101 -C(O)NR 101 R 102 5-6 membered heterocyclic groups; among which, R 101 and R 102Independently selected from: H, C1-C6 alkyl; the H on the 5-6 membered heterocyclic group is optionally substituted by one or more groups selected from: =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl.
[0044] More specifically, in the definition of R1, the substituted or unsubstituted 5-6 membered heterocyclic group has the following structure:
[0045] R 103 Selected from: H, C1-C6 alkyl, C1-C6 haloalkyl.
[0046] In some embodiments of the present invention, R1 is...
[0047] Specifically, each R2 is independently selected from: H, =O, halogen, C1-C6 alkyl (such as methyl), C1-C6 haloalkyl; in some embodiments of the present invention, R2 is selected from: H, =O, methyl. In some embodiments of the present invention, R2 is H.
[0048] In some embodiments of the present invention, L1 is -C(=O)NR L -
[0049] More specifically, R L Selected from: H, C1-C6 alkyl, -(C0-C6 alkylene)-(C3-C6 cycloalkyl).
[0050] In some embodiments of the present invention, L1 is -C(=O)NH-.
[0051] Specifically, ring B is a benzene ring, a 5-6 membered monocyclic heteroaromatic ring (such as pyridine, pyrazole, thiadiazole), or an 8-10 membered fused heterocyclic ring (such as a bicyclic ring fused with other rings, such as a benzene ring, pyridine, pyrazole, thiadiazole, etc.).
[0052] More specifically, Some are selected from the following structure:
[0053] in,
[0054] R 303 Selected from: H, halogen, cyano, hydroxyl, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxy-substituted alkyl, C1-C6 alkoxy, C1-C6 alkoxy-substituted alkyl, C1-C6 amino-substituted alkyl, C1-C6 amide-substituted alkyl, -S(O)2-NR 306 R 307 -C(O)(C0-C6 alkyl), -N(R) 306-C1-C6 amide-substituted alkyl, imidazolyl, thiazolyl, -C(O)NR 306 R 307 -NR 306 C(O)-R 307 ;R 306 R 307 Independently selected from: H, C1-C6 alkyl, -C(O)(C1-C6 alkyl), -(C0-C6 alkylene)-(C3-C6 cycloalkyl), -(C0-C6 alkylene)-(4-8 membered heterocyclic group); wherein the H in the C1-C6 alkyl, 4-8 membered heterocyclic group, imidazolyl, thiazolyl is optionally substituted by one or more groups selected from: halogen, cyano, -N(C0-C6 alkyl)(C0-C6 alkyl), -(C0-C6 alkylene)-(C3-C6 cycloalkyl), C1-C6 alkyl, C1-C6 haloalkyl, -C(O)(C1-C6 alkylene)-O-(C0-C6 alkyl);
[0055] R 304 It has the definition of R3 mentioned above;
[0056] R 305 Selected from: H, C1-C6 alkyl groups.
[0057] In some embodiments of the present invention, R 303 Selected from: -C(O)N(C0-C6 alkyl)(R 306 ), imidazole group, thiazolyl group; wherein the H in the imidazole group or thiazolyl group is optionally substituted by one or more groups selected from the following: C1-C6 alkyl, C1-C6 haloalkyl.
[0058] More specifically, R 306 Selected from: H, C1-C6 cyanosubstituted alkyl, -C(O)(C1-C6 alkylene)-N(C0-C6 alkyl)(C0-C6 alkyl), Among them, R 13 Selected from: H, C1-C6 alkyl, C1-C6 cyanosubstituted alkyl, -(C0-C6 alkylene)-(C3-C6 cycloalkyl), -C(O)(C1-C6 alkylene)-O-(C0-C6 alkyl), R 14 Selected from: H, halogen, cyano, R 15 Selected from: H, C1-C6 alkyl, C1-C6 haloalkyl, R 16 Selected from: H, C1-C6 alkyl groups, R 17 Selected from: H, C1-C6 alkyl groups, R 18 Selected from: H, C1-C6 alkyl, -(C1-C6 alkylene)-O-(C1-C6 alkyl).
[0059] In some embodiments of the present invention, R 303 Selected from:
[0060] In some embodiments of the present invention, R 304 Selected from: H, halogens (such as F), C1-C6 alkyl groups, C1-C6 haloalkyl groups; more specifically, R 304 It can be H or F.
[0061] In some embodiments of the present invention Some are selected from the following structure:
[0062] In some embodiments of the present invention, the compound has the following structure:
[0063] In a second aspect of the invention, a pharmaceutical composition is provided comprising the compound described in the first aspect or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate thereof, and one or more pharmaceutically acceptable excipients.
[0064] Specifically, the pharmaceutically acceptable excipients may be selected from one or more of the following: fillers, binders, lubricants, disintegrants, antioxidants, buffers, antibacterial agents, suspending agents, solubilizers, thickeners, stabilizers, and preservatives.
[0065] Specifically, the pharmaceutical composition can be administered via any suitable route of administration, such as gastrointestinal administration (e.g., oral, sublingual, rectal administration) or non-gastrointestinal administration (e.g., intravenous, intramuscular, intranasal, intraocular, intracerebral, intravaginal, intraperitoneal, transdermal, subcutaneous, intradermal, respiratory tract administration, etc.).
[0066] In some embodiments of the present invention, the pharmaceutical composition is an oral formulation, including, but not limited to, tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, oral tablets, etc.), pills, powders, granules, capsules (including soft capsules, microcapsules), lozenges, syrups, liquids, emulsions, suspensions, and controlled-release formulations (e.g., instantaneous-release formulations, sustained-release formulations, sustained-release microcapsules).
[0067] In some embodiments of the present invention, the pharmaceutical composition is an injectable preparation (e.g., subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection).
[0068] In other embodiments of the invention, the pharmaceutical composition is an intravenous infusion, a transdermal absorption formulation, a lotion, a suppository (e.g., a rectal suppository, a vaginal suppository), a nasal preparation, a pulmonary preparation (inhaler), an eye drop, etc.
[0069] Specifically, the pharmaceutical composition is preferably in unit dosage form. In this form, the formulation is further divided into unit doses containing an appropriate amount of the active ingredient. The unit dosage form can be a capsule, tablet, or any dosage form; alternatively, the unit dosage form can also be a packaged formulation, such as tablets, capsules, and powders packaged in vials or ampoules.
[0070] Specifically, the amount of the active ingredient in the unit dose formulation may be varied or adjusted from 0.1 mg to 1000 mg (e.g., 0.1, 1, 5, 10, 20, 40, 50, 100, 200, 400, 500, 1000 mg), depending on the specific application and potency of the active ingredient. If desired, the composition may also contain other suitable therapeutic agents.
[0071] A third aspect of the invention provides the use of the compound described in the first aspect or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, or solvate thereof in the preparation of a medicament for the prevention and / or treatment of STAT6-related diseases.
[0072] Specifically, the diseases include, but are not limited to: autoimmune diseases, inflammatory diseases, allergic diseases, tumors, and fibrotic diseases.
[0073] Specifically, the autoimmune diseases include, but are not limited to: organ-specific autoimmune diseases and systemic autoimmune diseases, such as autoimmune diabetes (also known as type 1 diabetes or insulin-dependent diabetes), systemic lupus erythematosus, systemic vasculitis, regional enteritis, cardiomyopathy, hemolytic anemia, fibromyalgia, Graves' disease, ulcerative colitis, Crohn's disease, multiple sclerosis, myasthenia gravis, myositis, neutropenia, psoriasis, chronic fatigue syndrome, juvenile arthritis, juvenile diabetes, scleroderma, psoriatic arthritis, Sjögren's syndrome, rheumatic fever, and rheumatoid arthritis. Arthritis, sarcoidosis, idiopathic thrombocytopenic purpura (ITP), Hashimoto's disease, mixed connective tissue disease, interstitial cystitis, pernicious anemia, leukoencephalitis, alopecia areata, ankylosing spondylitis, primary biliary cirrhosis, anti-GBM nephritis, anti-TBM nephritis, antiphospholipid syndrome, polymyalgia rheumatica, polymyositis, autoimmune Addison's disease, chronic active hepatitis, vitiligo, psoriasis, autoimmune hyperlipidemia, autoimmune myocarditis, temporal arteritis, autoimmune thyroid disease, axonal and neuronal neuropathy, Bechtel's disease, bullous pemphigoid, allergic asthma, osteoarthritis, Chagas disease Uveitis, chronic inflammatory demyelinating polyneuropathy (CIDP), cicatricial pemphigoid / benign mucosal pemphigoid, Kurgan syndrome, congenital heart block, Coxsackie virus myocarditis, demyelinating neuropathy, dermatomyositis, discoid lupus, lens antigenic uveitis, polyarteritis nodosa, Deslesler syndrome, idiopathic mixed cryoprecipitate globulinemia, Evans syndrome, pulmonary hemorrhage nephritis syndrome, allergic rhinitis, infectious neuritis, hypogammaglobulinemia, inclusion body myositis, vesicculobullous dermatitis, Wegener's granulomatosis, Meniere's disease Diseases including Lambert-Eton syndrome, Mollen's ulcer, atypical celiac disease, ocular cicatricial pemphigoid, pemphigus vulgaris, perivenous encephalomyelitis, post-pericardiotomy syndrome, scleritis, sperm-testis autoimmune disease, stiff-person syndrome, subacute bacterial endocarditis (SBE), sympathetic ophthalmia, transverse myelitis and necrotizing myelopathy, type I autoimmune polygonatum syndrome, type II autoimmune polygonatum syndrome, pernicious anemia and endometriosis; especially, one or more of systemic lupus erythematosus, systemic vasculitis, ulcerative colitis, Crohn's disease, multiple sclerosis, and rheumatoid arthritis.
[0074] Specifically, the inflammatory diseases and allergic diseases include, but are not limited to: chronic obstructive pulmonary disease, atopic dermatitis, asthma, bullous pemphigoid, nasal polyps, chronic sinusitis, allergic rhinitis, eosinophilic esophagitis, prurigo, and urticaria; particularly, one or more of chronic obstructive pulmonary disease, atopic dermatitis, and asthma.
[0075] Specifically, the tumors include, but are not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colonic adenocarcinoma, rectal adenocarcinoma, pancreatic cancer, pancreatic adenocarcinoma, breast cancer, ovarian cancer, ovarian serous cystadenocarcinoma, prostate cancer, squamous cell carcinoma, head and neck squamous cell carcinoma, colorectal cancer, and lymphoma (e.g., diffuse large B-cell lymphoma (DLBLC)). BCL, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma (MALT), small lymphocytic lymphoma / chronic lymphocytic leukemia, mantle cell lymphoma (MCL), T / NK cell lymphoma, leukemia (e.g., chronic lymphocytic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute monocytic leukemia), liver cancer, glioblastoma, melanoma, myeloma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, nipple cancer. Papillary carcinoma, cystic adenocarcinoma, medullary carcinoma, bronchial carcinoma, renal cell carcinoma, liver cancer, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular cancer, testicular germ cell tumor, lung cancer, small cell lung cancer, lung adenocarcinoma, bladder cancer, epithelial carcinoma, glioma (e.g., low-grade glioma of the brain), glioblastoma (e.g., glioblastoma multiforme), astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma Meningioma, melanoma, uveal melanoma, neuroblastoma, retinoblastoma, thyroid cancer, endometrial cancer of the uterine body, uterine carcinosarcoma, pheochromocytoma, paraganglioma; especially, solitary fibroma, breast cancer, prostate cancer, colon cancer, lung cancer (such as non-small cell lung cancer), gastric cancer, hepatocellular carcinoma, melanoma, malignant lymphoma (as described in Yang Xianhe, Wu Liqing. Research progress on the relationship between STAT6 and tumors [J]. Journal of Clinical and Experimental Pathology, 2019, 35(1):68-70).
[0076] Specifically, the fibrotic diseases include, but are not limited to: pulmonary fibrosis, renal fibrosis, hepatic fibrosis, bladder fibrosis, atrial fibrosis, endocardial myocardial fibrosis, glial scars, arterial stiffness, joint fibrosis, Crohn's disease, Dupuytren contracture, keloid fibrosis, mediastinal fibrosis, myelofibrosis, Peroni disease, renal systemic fibrosis, progressive massive fibrosis, retroperitoneal fibrosis, scleroderma / systemic sclerosis, adhesive capsulitis, and fibrotic lesions of the skin; particularly pulmonary fibrosis, renal fibrosis, and fibrotic lesions of the skin.
[0077] In some embodiments of the present invention, the disease is a lung disease, such as pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, acute lung injury, or acute lung inflammation.
[0078] A fourth aspect of the invention provides a method for preventing and / or treating STAT6-related diseases, comprising administering to a subject in need the compound of the first aspect or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate, or pharmaceutical composition of the second aspect thereof.
[0079] Specifically, the subjects are mammals, such as humans.
[0080] Specifically, the disease is as described in the third aspect of the present invention.
[0081] Specifically, the administration can be carried out via any suitable route of administration, such as gastrointestinal administration (e.g., oral, sublingual, rectal administration) or non-gastrointestinal administration (e.g., intravenous, intramuscular, intranasal, intraocular, intracerebral, intravaginal, intraperitoneal, transdermal, subcutaneous, intradermal, respiratory tract administration, etc.), especially oral administration.
[0082] This invention provides a novel STAT6 inhibitor compound with excellent inhibitory activity, which has very good application prospects and value in the pharmaceutical field. Detailed Implementation
[0083] Unless otherwise defined, all scientific and technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art.
[0084] The term "alkyl" refers to a straight-chain or branched hydrocarbon radical that does not contain unsaturated bonds and is connected to the rest of the molecule by single bonds. Typical alkyl groups contain 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl, etc. If an alkyl group is substituted with a cycloalkyl group, the corresponding radical is a "cycloalkylalkyl" radical, such as cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, etc. If an alkyl group is substituted with an aryl group, the corresponding radical is an "aralkylalkyl" radical, such as benzyl, diphenylmethyl, or phenethyl. If an alkyl group is substituted with a heterocyclic group, the corresponding radical is a "heterocyclicalkyl" radical. In this invention, CO alkyl refers to H, i.e., CO-C. 10 Alkyl groups include H and C1-C 10 alkyl.
[0085] The term "alkylene" refers to a hydrocarbon group (divalent alkyl) formed by the loss of two hydrogen atoms from an alkane molecule. It can be straight-chain or branched and is connected to the rest of the molecule by a single bond. Typical alkylene groups described herein have 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) carbon atoms, preferably 1 to 6 carbon atoms, such as methylene (-CH2-), ethylene, propylene, butylene, etc. In this invention, CO alkylene refers to a single bond, i.e., CO-C. 10 Alkyl groups include single bonds and C1-C bonds. 10 Alkylene.
[0086] The term "alkoxy" refers to a substituent formed when a hydrogen atom in a hydroxyl group is replaced by an alkyl group. Typical alkoxy groups contain 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms, such as methoxy, ethoxy, propoxy, butoxy, etc.
[0087] The term "alkylamine" refers to a substituent formed when one or two hydrogen atoms of an amino group (-NH2) are replaced by an alkyl group, such as an alkylamine group containing 1-10 carbon atoms, for example...
[0088] The term "cycloalkyl" refers to a saturated or partially saturated (especially saturated) monocyclic or polycyclic group that may contain 1 to 4 monocyclic and / or fused rings and 3 to 18 carbon atoms, preferably 3 to 10 (e.g., 3, 4, 5, 6, 7, 8, 9, 10) carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl.
[0089] The term "aryl" refers to a monocyclic or polycyclic free radical, including polycyclic free radicals containing a monoaryl group and / or a fused aryl group, such as those containing 1-3 monocyclic or fused rings and 6-18 (e.g., 6, 8, 10, 12, 14, 16, 18) carbon ring atoms. Typical aryl groups are those containing 6-12 carbon ring atoms, such as phenyl, naphthyl, biphenyl, and indenyl. "Arylidene" refers to a divalent group derived from aromatic hydrocarbons by removing two hydrogen atoms.
[0090] The term "heterocyclic group" includes heteroaromatic and heterocyclic groups containing 1 to 3 monocyclic and / or fused rings and 3 to 18 ring atoms. Preferred heteroaromatic and heterocyclic groups contain 5 to 10 ring atoms. Suitable heteroaryl groups in the compounds of the present invention contain 1, 2, or 3 heteroatoms selected from N, O, or S atoms. Examples of heteroaryl groups, such as, but not limited to, coumarins, including 8-coumarins; quinolinyl groups, including 8-quinolinyl, isoquinolinyl, pyridyl, pyrazinyl, pyrazolyl, pyrimidinyl, furanyl, pyrroloyl, thiopheneyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, imidazoleyl, indoleyl, isoindoleyl, indazoleyl, inazinyl, phthalazinyl, pteridinyl, purineyl, oxadiazolyl, thiadiazolyl, furazolidyl, pyridazinyl, triazinyl, cenolinyl, benzimidazolyl, benzofuranyl, benzofuranyl, benzothiopheneyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphridinyl, and furanopyridinyl, etc. Suitable heterocyclic groups in the compounds of the present invention contain one, two, or three heteroatoms selected from N, O, or S atoms. Examples of heterocyclic groups, such as, but not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuran, tetrahydrothiophenyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, oxothiocyclohexyl, piperazine, aziridine, oxocyclobutyl, thiocyclobutyl, high-piperidinyl, oxocyclopropane, thiocyclopropane, acrylonitrile, oxoaziridine, diacylonitrile, triacylonitrile, 1,2,3,6-tetracyclyl Hydropyridyl, 2-pyrrolinyl, 3-pyrrolinyl, dihydroindolyl, 2H-pyranyl, 4H-pyranyl, dioxacyclohexyl, 1,3-dioxapentyl, pyrazolinyl, dithiaalkyl, dithiopentyl, dihydropyranyl, dihydrothiophenyl, pyrazolinyl, imidazolinyl, imidazolinyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, 3H-indolyl and quinazinyl, etc.
[0091] The above-mentioned groups can be replaced by one or more suitable groups at one or more available positions, such as: OR', =O, SR', SOR', SO2R', OSO2R', OSO3R', NO2, NHR', N(R')2, =N-R', N(R')COR', N(COR')2, N(R')SO2R', N(R')C(=NR')N(R')R', N3, CN, halogen, COR', COOR', OCOR', OCOOR', OCONHR', OCON(R')2, CONHR', CON(R')2, CON(R')OR', CON(R')SO2R', PO(OR')2, PO(OR')R', PO(OR')(N(R')R'), Cl-C 12 Alkyl, C3-C 10cycloalkyl, C2-C 12 alkenyl, C2-C 12 Alkynyl, aryl, and heterocyclic groups, wherein each R' group is independently selected from: hydrogen, OH, NO2, NH2, SH, CN, halogen, COH, COalkyl, COOH, C1-C 12 Alkyl, C3-C 10 cycloalkyl, C2-C 12 alkenyl, C2-C 12 Alkynyl, aryl, and heterocyclic groups. These groups are themselves substituted, and the substituents can be selected from the aforementioned list.
[0092] "Halogen" refers to bromine, chlorine, iodine, or fluorine. Haloalkyl refers to a group in which the hydrogen atom on the alkyl group is replaced by a halogen atom (F, Cl, Br, I), such as -CH2Rh, -CHRh2, -CRh3, where Rh is F, Cl, Br, or I; such as -CF3.
[0093] The term "pharmaceutically acceptable salt" refers to an acidic or basic salt that is theoretically non-toxic, non-irritating, and non-allergenic, and that can achieve or provide clinically acceptable pharmacokinetic, absorption, distribution, and metabolic properties of a drug molecule to achieve its intended purpose. The salts described in this invention include pharmaceutically acceptable acidic or basic salts of compounds with acidic, basic, or amphoteric groups. A list of suitable salts can be found in SM Birge, et al., J. Pharm. Sci., 66, 1-19 (1977).
[0094] The pharmaceutically acceptable salts described in this invention include acid addition salts and base addition salts.
[0095] The acid addition salts include, but are not limited to, salts from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, and phosphonic acid, as well as salts from organic acids such as aliphatic monocarboxylic acids and dicarboxylic acids, phenyl-substituted alkanic acids, hydroxyalkanic acids, alkanedioic acids, aromatic acids, and aliphatic and aromatic sulfonic acids. Therefore, these salts include, but are not limited to, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, hydrochlorides, hydrobromates, iodates, acetates, propionates, octanoates, isobutyrates, oxalates, malonates, succinates, octanoates, sebacic acid salts, fumarates, maleates, amygdalinates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, maleates, tartrates, and methanesulfonates, as well as salts of amino acids such as arginine salts, gluconates, and galacturonic acids. Acid addition salts can be prepared by contacting a sufficient amount of the desired acid in a conventional manner to form a salt. The free base can be regenerated by contacting the salt with a base, and the free base can be separated in a conventional manner.
[0096] The base addition salts described in this invention refer to salts formed with metals or amines, such as hydroxides of alkali metals and alkaline earth metals, or with organic amines. Examples of metals used as cations include, but are not limited to, sodium, potassium, magnesium, and calcium. Suitable amines include, but are not limited to, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine (ethane-1,2-diamine), N-methylglucosamine, and procaine. Base addition salts can be prepared by contacting a sufficient amount of the desired base in a conventional manner to form a salt. The free acid form can be regenerated by contacting the salt form with an acid, and the free acid can be separated in a conventional manner.
[0097] The term "solvent" should be understood to refer to any form of the compounds of the present invention, wherein the compounds are linked to another molecule (usually a polar solvent) by a non-covalent bond, particularly including hydrates and alcohols, such as methanols. Hydrates are preferred solvates.
[0098] The term "prodrug" is used in its broad sense and encompasses derivatives that can be converted into the compounds of this invention in vivo. Examples of prodrugs include, but are not limited to, derivatives and metabolites of compounds, including biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable acylureas, and biohydrolyzable phosphate ester analogs. Preferably, prodrugs having a carboxyl functional group are lower alkyl esters of carboxylic acids. The carboxylic acid esters are readily obtained by esterification of any carboxylic acid moiety present in the molecule. Prodrugs can generally be prepared by known methods, such as those described in Burger's "Medicinal Chemistry and Drug Discovery, 6th Edition" (Donald J. Abraham ed., 2001, Wiley) and "Design and Applications of Prodrugs" (H. Bundgaard ed., 1985, Harwood Academic Publishers).
[0099] The term "stereoisomer" includes enantiomers, diastereomers, and geometric isomers. Some compounds of the present invention have cyclic hydrocarbon groups that can be substituted on more than one carbon atom; in this case, all their geometric forms, including cis and trans, and mixtures thereof, are within the scope of the present invention.
[0100] The term "deuterated compound" refers to a compound that is substituted with deuterium, where "substituted with deuterium" means that one or more hydrogen atoms are replaced with a corresponding number of deuterium atoms.
[0101] It should be recognized that, depending on the source of the chemical materials used in the synthesis, there are variations in the natural isotopic abundance in the synthesized compounds. Therefore, the compounds of the present invention will inherently contain small amounts of deuterated isotopes. Despite this variation, the concentrations of these naturally abundant stable hydrogen and carbon isotopes are low and insignificant compared to the degree of stable isotopic substitution in the compounds of the present invention. See, for example, Wada, E et al., Seikagaku, 1994, 66:15; Gannes, LZ et al., Comp Biochem Physiol Mol Integr Physiol, 1998, 119:725.
[0102] In the compounds of this invention, any atom not specifically designated as deuterium is present at its natural isotopic abundance. Unless otherwise stated, when a position is specifically designated as "H" or "hydrogen", that position should be understood as having hydrogen according to its natural abundance isotopic composition. Similarly, unless otherwise stated, when a position is specifically designated as "D" or "deuterium", that position should be understood as having deuterium at an abundance at least 3000 times greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 45% deuterium doping).
[0103] The term "isotope enrichment coefficient" refers to the ratio between the isotopic abundance of a particular isotope and its natural abundance.
[0104] In other embodiments, the compounds of the present invention have an isotopic enrichment factor for each specified deuterium atom of at least 3500 (52.5% deuterium doping at each specified deuterium atom), at least 4000 (60% deuterium doping), at least 4500 (67.5% deuterium doping), at least 5000 (75% deuterium doping), at least 5500 (82.5% deuterium doping), at least 6000 (90% deuterium doping), at least 6333.3 (95% deuterium doping), at least 6466.7 (97% deuterium doping), at least 6600 (99% deuterium doping), or at least 6633.3 (99.5% deuterium doping).
[0105] The term "isotope" refers to a substance whose chemical structure differs from that of a specific compound of the present invention only in terms of its isotopic composition.
[0106] The terms “patient” or “subject”, etc., may be used interchangeably herein to refer to any animal or its cells, whether in vitro or in situ, treated according to the methods described herein. Specifically, the aforementioned animals include mammals, such as rats, mice, guinea pigs, rabbits, dogs, monkeys, or humans, especially humans.
[0107] The term "treatment" refers to the prevention, cure, reversal, reduction, mitigation, minimization, suppression, cessation, and / or cessation of one or more clinical symptoms of a disease after its onset.
[0108] The term "prevention" refers to the treatment taken before a disease develops to avoid, minimize, or prevent the disease from developing or progressing.
[0109] The term "STAT6-related diseases" primarily refers to diseases associated with abnormal STAT6 activity, particularly those that can be prevented and / or treated by inhibiting STAT6.
[0110] The term "tumor" refers to an abnormal mass of tissue that grows beyond and out of harmony with the growth of normal tissue. Tumors can be "benign" or "malignant," depending on characteristics such as the degree of cell differentiation (including morphology and function), growth rate, local invasion, and metastasis. "Benign tumors" are typically well-differentiated, characterized by slower growth than malignant tumors, and remain confined to their site of origin. Furthermore, benign tumors do not have the ability to infiltrate, invade, or metastasize to distant sites. In some cases, certain "benign" tumors may later develop into malignant tumors, possibly due to additional genetic alterations in a subset of the tumor's proliferative cells, and these tumors are called "precancerous tumors." "Malignant tumors" are typically poorly differentiated (anaplastic) and characterized by rapid growth, accompanied by progressive infiltration, invasion, and destruction of surrounding tissues. Furthermore, malignant tumors often have the ability to metastasize to distant sites.
[0111] The term “cancer” refers to a malignant tumor (Stedman’s Medical Dictionary, 25th ed.; Hensyled.; Williams & Wilkins: Philadelphia, 1990).
[0112] The term "autoimmune disease" refers to diseases caused by the body's immune response to its own antigens, resulting in damage to its own tissues.
[0113] The term "inflammation" refers to the body's defensive response to stimuli, manifested as redness, swelling, heat, pain, and functional impairment. It can be infectious inflammation caused by infection, or non-infectious inflammation not caused by infection, such as inflammation caused by immune responses (e.g., various types of hypersensitivity reactions, inflammation caused by some autoimmune diseases). The term "inflammatory disease" refers to a disease characterized by inflammation.
[0114] The term "fibrosis" refers to a pathological process caused by inflammation, resulting in necrosis of organ parenchymal cells and an abnormal increase and excessive deposition of extracellular matrix within the tissue. In severe cases, it can lead to tissue structural damage and organ sclerosis.
[0115] The term "STAT6 inhibitor" refers to a molecule that reduces, inhibits, or otherwise diminishes one or more biological activities of STAT6. Inhibition with a STAT6 inhibitor does not necessarily indicate complete elimination of STAT6 activity. STAT6 activity may be reduced by a significant amount compared to a control, for example, a reduction of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
[0116] All publications, patents, and published patent specifications cited in this article are incorporated herein in their entirety through citation.
[0117] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0118] Compound Synthesis Examples
[0119] Table 1. List of compounds and general analytical data
[0120] Example 1: Synthesis of Compound 1
[0121] 1.1 Synthesis of intermediate STAT6-1-001
[0122] Methyl 3-aminophenylacetate (CAS: 52913-11-8, 1.0 eq) was dissolved in N,N-dimethylformamide, followed by the addition of N-bromosuccinimide (NBS) (1.05 eq). The reaction was carried out at room temperature for 2 hours. After the reaction was completed as monitored by LC-MS, the reaction solution was diluted with ethyl acetate, washed once with saturated sodium bicarbonate, twice with water, and once with saturated brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-1-001.
[0123] 1.2 Synthesis of intermediate STAT6-1-002
[0124] Intermediate STAT6-1-001 (1.0 eq), methyl hydrazinoformate (1.2 eq), triethyl orthoacetate (1.2 eq), and p-toluenesulfonic acid (0.1 eq) were added to n-butanol, purged three times with nitrogen, and then heated to 120 °C for 16 hours. After the reaction was completed by LC-MS monitoring, the reaction solution was diluted with ethyl acetate, washed twice with water and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-1-002.
[0125] 1.3 Synthesis of intermediate STAT6-1-003
[0126] Intermediate STAT6-1-002 (1.0 eq) was dissolved in N,N-dimethylformamide, and NaH (2.0 eq) was added under ice bath conditions. After reacting for 1 hour, iodomethane (3.0 eq) was slowly added dropwise. After the addition was complete, the mixture was brought to room temperature and reacted for another 1 hour. After the reaction was monitored by LC-MS, the reaction solution was quenched with saturated ammonium chloride, diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-1-003.
[0127] 1.4 Synthesis of intermediate STAT6-1-004
[0128] Intermediate STAT6-1-003 (1.0 eq) was dissolved in tetrahydrofuran, and lithium aluminum hydride (1.0 eq) was slowly added dropwise at 0 °C. The system was reacted at 0 °C for 2 hours. After the reaction was completed by LC-MS monitoring, 10% NaOH aqueous solution was added to the system and stirred for 30 minutes. Then, sodium sulfate decahydrate was added and stirred for 30 minutes. After the reaction was completed, the mixture was diluted with ethyl acetate, washed twice with water and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-1-004.
[0129] 1.5 Synthesis of intermediate STAT6-1-005
[0130] Intermediate STAT6-1-004 (1.0 eq) was dissolved in N,N-dimethylformamide, and NaH (2.0 eq) was added under ice bath conditions. After reacting for 1 hour, benzyl bromide (3.0 eq) was slowly added dropwise. After the addition was complete, the mixture was brought to room temperature and reacted for another 1 hour. After the reaction was monitored by LC-MS, the reaction solution was quenched with saturated ammonium chloride, diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-1-005.
[0131] 1.6 Synthesis of intermediate STAT6-1-006
[0132] Intermediate STAT6-1-005 (1.0 eq), pinacol diborate (3.0 eq), Pd(dppf)Cl2 (0.2 eq), and potassium acetate (KOAc) (2.0 eq) were added to 1,4-dioxane. The mixture was purged with nitrogen three times, and then the temperature was raised to 80 °C for 4 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-1-006.
[0133] 1.7 Synthesis of intermediate STAT6-1-007
[0134] Intermediate STAT6-1-006 (1.0 eq), intermediate EX15-008 (1.0 eq), Pd(dppf)Cl2 (0.1 eq), and potassium carbonate (K2CO3) (2.0 eq) were added to 1,4-dioxane and water (4:1). The mixture was purged with nitrogen three times, and then the temperature was raised to 80 °C for 4 hours. After the reaction was monitored by LC-MS, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-1-007.
[0135] 1.8 Synthesis of intermediate STAT6-1-008
[0136] Intermediate STAT6-1-007 (1.0 eq) and Pd / C (0.1 eq) were added to ethanol, a hydrogen balloon was added, and the mixture was purged with hydrogen three times. The temperature was raised to 40 °C and reacted for 8 hours. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, and the resulting organic phase was concentrated under reduced pressure to obtain intermediate STAT6-1-008.
[0137] 1.9 Synthesis of intermediate STAT6-1-009
[0138] Intermediate STAT6-1-008 (1.0 eq), p-toluenesulfonic acid (p-TSOH) (0.01 eq), and Shvo's catalyst (0.05 eq) were added to toluene, purged three times with nitrogen, and then the mixture was heated to 110 °C and reacted for 24 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-1-009.
[0139] 1.10 Synthesis of Compound 1
[0140] Intermediate STAT6-1-009 (1.0 eq) and 3-amino-2-fluorobenzamide (2.0 eq) were added to Tol (toluene), and trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60 °C for 24 hours. After the reaction was completed by LC-MS monitoring, the reaction solution was quenched with water, filtered, and the resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 1.
[0141] Example 2: Synthesis of Compound 2
[0142] 2.1 Synthesis of intermediate STAT6-2-001
[0143] Methyl 3-aminophenylacetate (CAS: 52913-11-8, 1.0 eq) was dissolved in N,N-dimethylformamide, followed by the addition of N-bromosuccinimide (NBS) (1.05 eq). The reaction was carried out at room temperature for 2 hours. After the reaction was completed as monitored by LC-MS, the reaction solution was diluted with ethyl acetate, washed once with saturated sodium bicarbonate, twice with water, and once with saturated brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-2-001.
[0144] 2.2 Synthesis of intermediate STAT6-1-002
[0145] Intermediate STAT6-2-001 (1.0 eq), methyl hydrazinoformate (1.2 eq), triethyl orthoacetate (1.2 eq), and p-toluenesulfonic acid (0.1 eq) were added to n-butanol, purged three times with nitrogen, and then heated to 120 °C for 16 hours. After the reaction was completed by LC-MS monitoring, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-2-002.
[0146] 2.3 Synthesis of intermediate STAT6-2-003
[0147] Intermediate STAT6-2-002 (1.0 eq) was dissolved in N,N-dimethylformamide, and NaH (2.0 eq) was added under ice bath conditions. After reacting for 1 hour, iodomethane (3.0 eq) was slowly added dropwise. After the addition was complete, the mixture was brought to room temperature and reacted for another 1 hour. After the reaction was monitored by LC-MS, the reaction solution was quenched with saturated ammonium chloride, diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-2-003.
[0148] 2.4 Synthesis of intermediate STAT6-2-004
[0149] Intermediate STAT6-2-003 (1.0 eq) was dissolved in tetrahydrofuran, and lithium aluminum hydride (1.0 eq) was slowly added dropwise at 0 °C. The system was reacted at 0 °C for 2 hours. After the reaction was completed by LC-MS monitoring, 10% NaOH aqueous solution was added to the system and stirred for 30 minutes. Then, sodium sulfate decahydrate was added and stirred for 30 minutes. After the reaction was completed, the mixture was diluted with ethyl acetate, washed twice with water and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-2-004.
[0150] 2.5 Synthesis of intermediate STAT6-2-005
[0151] Intermediate STAT6-2-004 (1.0 eq) was dissolved in N,N-dimethylformamide, and NaH (2.0 eq) was added under ice bath conditions. After reacting for 1 hour, benzyl bromide (3.0 eq) was slowly added dropwise. After the addition was complete, the mixture was brought to room temperature and reacted for another 1 hour. After the reaction was monitored by LC-MS, the reaction solution was quenched with saturated ammonium chloride, diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-2-005.
[0152] 2.6 Synthesis of intermediate STAT6-2-006
[0153] Intermediate STAT6-2-005 (1.0 eq), pinacol diborate (3.0 eq), Pd(dppf)Cl2 (0.2 eq), and potassium acetate (KOAc) (2.0 eq) were added to 1,4-dioxane. The mixture was purged with nitrogen three times, and then the temperature was raised to 80 °C for 4 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-2-006.
[0154] 2.7 Synthesis of intermediate STAT6-2-007
[0155] Intermediate STAT6-2-006 (1.0 eq), intermediate EX15-008 (1.0 eq), Pd(dppf)Cl2 (0.1 eq), and potassium carbonate (K2CO3) (2.0 eq) were added to 1,4-dioxane and water (4:1). The mixture was purged with nitrogen three times, and then the temperature was raised to 80 °C for 4 hours. After the reaction was completed by LC-MS monitoring, the reaction solution was diluted with ethyl acetate, washed twice with water, and washed once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then subjected to column chromatography to obtain intermediate STAT6-2-007.
[0156] 2.8 Synthesis of intermediate STAT6-2-008
[0157] Intermediate STAT6-2-007 (1.0 eq) and Pd / C (0.1 eq) were added to ethanol, a hydrogen balloon was added, and the mixture was purged with hydrogen three times. The temperature was raised to 40 °C and reacted for 8 hours. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, and the resulting organic phase was concentrated under reduced pressure to obtain intermediate STAT6-2-008.
[0158] 2.9 Synthesis of intermediate STAT6-2-009
[0159] Intermediate STAT6-2-008 (1.0 eq), p-toluenesulfonic acid (p-TSOH) (0.01 eq), and Shvo's catalyst (0.05 eq) were added to toluene, purged three times with nitrogen, and then the mixture was heated to 110 °C and reacted for 24 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-2-009.
[0160] 2.10 Synthesis of Compound 2
[0161] Intermediate STAT6-2-009 (1.0 eq) and 3-amino-2-fluorobenzamide (2.0 eq) were added to Tol, and trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60 °C for 24 hours. After the reaction was completed by LC-MS monitoring, the reaction solution was quenched with water, filtered, and the resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 2.
[0162] Example 3: Synthesis of Compound 3
[0163] Intermediate STAT6-1-009 (prepared in Example 1, 1.0 eq) and 3-amino-4-fluorobenzamide (2.0 eq) were added to Tol. Trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60°C for 24 hours. After the reaction was completed, the reaction solution was quenched with water and filtered. The resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 3.
[0164] Example 4: Synthesis of Compound 4
[0165] Intermediate STAT6-1-009 (prepared in Example 1, 1.0 eq) and 3-aminobenzamide (2.0 eq) were added to Tol. Trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60°C for 24 hours. After the reaction was completed, the reaction solution was quenched with water and filtered. The resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 4.
[0166] Example 5: Synthesis of Compound 5
[0167] Intermediate STAT6-2-009 (prepared in Example 2, 1.0 eq) and 3-aminobenzamide (2.0 eq) were added to Tol. Trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60°C for 24 hours. After the reaction was completed, the reaction solution was quenched with water and filtered. The resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 5.
[0168] Example 6: Synthesis of Compound 6
[0169] Intermediate STAT6-2-009 (prepared in Example 2, 1.0 eq) and 3-amino-4-fluorobenzamide (2.0 eq) were added to Tol. Trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60°C for 24 hours. After the reaction was completed, the reaction solution was quenched with water and filtered. The resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 6.
[0170] Example 7: Synthesis of Compound 7
[0171] Intermediate STAT6-2-009 (prepared in Example 2, 1.0 eq) and 3-amino-N-methylbenzamide (2.0 eq) were added to Tol. Trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60°C for 24 hours. After the reaction was completed, the reaction solution was quenched with water and filtered. The resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 7.
[0172] Example 8: Synthesis of Compound 8
[0173] 8.1 Synthesis of intermediate STAT6-8-001
[0174] Methyl 3-aminophenylpropionate (CAS: 35418-08-7, 1.0 eq) was dissolved in N,N-dimethylformamide, followed by the addition of N-bromosuccinimide (NBS) (1.05 eq). The reaction was carried out at room temperature for 2 hours. After the reaction was completed as monitored by LC-MS, the reaction solution was diluted with ethyl acetate, washed once with saturated sodium bicarbonate, twice with water, and once with saturated brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-8-001.
[0175] 8.2 Synthesis of intermediate STAT6-8-002
[0176] Intermediate STAT6-8-001 (1.0 eq), methyl hydrazinoformate (1.2 eq), triethyl orthoacetate (1.2 eq), and p-toluenesulfonic acid (0.1 eq) were added to n-butanol, purged three times with nitrogen, and then the mixture was heated to 120 °C and reacted for 16 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-8-002.
[0177] 8.3 Synthesis of intermediate STAT6-8-003
[0178] Intermediate STAT6-8-002 (1.0 eq) was dissolved in N,N-dimethylformamide, and NaH (2.0 eq) was added under ice bath conditions. After reacting for 1 hour, iodomethane (3.0 eq) was slowly added dropwise. After the addition was complete, the mixture was brought to room temperature and reacted for another 1 hour. After the reaction was monitored by LC-MS, the reaction solution was quenched with saturated ammonium chloride, diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-8-003.
[0179] 8.4 Synthesis of intermediate STAT6-8-004
[0180] Intermediate STAT6-8-003 (1.0 eq) was dissolved in tetrahydrofuran, and lithium aluminum hydride (1.0 eq) was slowly added dropwise at 0 °C. The system was reacted at 0 °C for 2 hours. After the reaction was completed by LC-MS monitoring, 10% NaOH aqueous solution was added to the system and stirred for 30 minutes. Then, sodium sulfate decahydrate was added and stirred for 30 minutes. After the reaction was completed, the mixture was diluted with ethyl acetate, washed twice with water and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-8-004.
[0181] 8.5 Synthesis of intermediate STAT6-8-005
[0182] Intermediate STAT6-8-004 (1.0 eq) was dissolved in N,N-dimethylformamide, and NaH (2.0 eq) was added under ice bath conditions. After reacting for 1 hour, benzyl bromide (3.0 eq) was slowly added dropwise. After the addition was complete, the mixture was brought to room temperature and reacted for another 1 hour. After the reaction was monitored by LC-MS, the reaction solution was quenched with saturated ammonium chloride, diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-8-005.
[0183] 8.6 Synthesis of intermediate STAT6-8-006
[0184] Intermediate STAT6-8-005 (1.0 eq), pinacol diborate (3.0 eq), Pd(dppf)Cl2 (0.2 eq), and potassium acetate (KOAc) (2.0 eq) were added to 1,4-dioxane. The mixture was purged with nitrogen three times, and then the temperature was raised to 80 °C for 4 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-8-006.
[0185] 8.7 Synthesis of intermediate STAT6-8-007
[0186] Intermediate STAT6-8-006 (1.0 eq), intermediate EX15-008 (1.0 eq), Pd(dppf)Cl2 (0.1 eq), and potassium carbonate (K2CO3) (2.0 eq) were added to 1,4-dioxane and water (4:1). The mixture was purged with nitrogen three times, and then the temperature was raised to 80 °C for 4 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-8-007.
[0187] 8.8 Synthesis of intermediate STAT6-8-008
[0188] Intermediate STAT6-8-007 (1.0 eq) and Pd / C (0.1 eq) were added to ethanol, a hydrogen balloon was added, and the mixture was purged with hydrogen three times. The temperature was raised to 40 °C and reacted for 8 hours. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, and the resulting organic phase was concentrated under reduced pressure to obtain intermediate STAT6-8-008.
[0189] 8.9 Synthesis of intermediate STAT6-8-009
[0190] Intermediate STAT6-8-008 (1.0 eq), p-toluenesulfonic acid (p-TSOH) (0.01 eq), and Shvo's catalyst (0.05 eq) were added to toluene, purged three times with nitrogen, and then the mixture was heated to 110 °C and reacted for 24 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-8-009.
[0191] 8.10 Synthesis of Compound 8
[0192] Intermediate STAT6-8-009 (1.0 eq) and 3-amino-2-fluorobenzamide (2.0 eq) were added to Tol, and trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60 °C for 24 hours. After the reaction was completed by LC-MS monitoring, the reaction solution was quenched with water, filtered, and the resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 8.
[0193] Example 9: Synthesis of Compound 9
[0194] Intermediate STAT6-2-009 (prepared in Example 2, 1.0 eq) and 2-aminopyridine (2.0 eq) were added to Tol. Trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60°C for 24 hours. After the reaction was completed, the reaction solution was quenched with water and filtered. The resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 9.
[0195] Example 10: Synthesis of Compound 10
[0196] 10.1 Synthesis of intermediate STAT6-10-001
[0197] Methyl 2-bromo-5-aminobenzoate (CAS: 6942-37-6, 1.0 eq), methyl hydrazinoformate (1.2 eq), triethyl orthoacetate (1.2 eq), and p-toluenesulfonic acid (0.1 eq) were added to n-butanol, purged three times with nitrogen, and then heated to 120 °C for 16 hours. After the reaction was monitored by LC-MS, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-10-001.
[0198] 10.2 Synthesis of intermediate STAT6-10-002
[0199] Intermediate STAT6-10-001 (1.0 eq) was dissolved in N,N-dimethylformamide, and NaH (2.0 eq) was added under ice bath conditions. After reacting for 1 hour, iodomethane (3.0 eq) was slowly added dropwise. After the addition was complete, the mixture was brought to room temperature and reacted for another 1 hour. After the reaction was monitored by LC-MS, the reaction solution was quenched with saturated ammonium chloride, diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-10-002.
[0200] 10.3 Synthesis of intermediate STAT6-10-003
[0201] Intermediate STAT6-10-002 (1.0 eq) was dissolved in tetrahydrofuran, and lithium aluminum hydride (1.0 eq) was slowly added dropwise at 0 °C. The system was reacted at 0 °C for 2 hours. After the reaction was completed by LC-MS monitoring, 10% NaOH aqueous solution was added to the system and stirred for 30 minutes. Then, sodium sulfate decahydrate was added and stirred for 30 minutes. After the reaction was completed, the mixture was diluted with ethyl acetate, washed twice with water and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, column chromatography was performed to obtain intermediate STAT6-10-003.
[0202] 10.4 Synthesis of intermediate STAT6-10-004
[0203] Intermediate STAT6-10-003 (1.0 eq) was dissolved in dichloromethane, and PPTS (0.1 eq) was added under ice bath conditions, followed by slow dropwise addition of DHP (1.5 eq). After the addition was complete, the mixture was brought to room temperature and reacted for 1 hour. After the reaction was completed, monitored by LC-MS, the reaction solution was quenched with saturated ammonium chloride, diluted with dichloromethane, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-10-004.
[0204] Synthesis of intermediate STAT6-10-005 (10.5)
[0205] Intermediate STAT6-10-004 (1.0 eq), pinacol diborate (3.0 eq), Pd(dppf)Cl2 (0.2 eq), and potassium acetate (KOAc) (2.0 eq) were added to 1,4-dioxane. The mixture was purged with nitrogen three times, and then the temperature was raised to 80 °C for 4 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-10-005.
[0206] 10.6 Synthesis of intermediate STAT6-1-006
[0207] Intermediate STAT6-10-005 (1.0 eq), intermediate EX15-008 (1.0 eq), Pd(dppf)Cl2 (0.1 eq), and potassium carbonate (K2CO3) (2.0 eq) were added to 1,4-dioxane and water (4:1). The mixture was purged with nitrogen three times, and then the temperature was raised to 80 °C for 4 hours. After the reaction was monitored by LC-MS, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-10-006.
[0208] Synthesis of intermediate STAT6-10-007 (10.7)
[0209] Intermediate STAT6-10-006 (1.0 eq) and HCl / Diox (10 e. q.) were added to dichloromethane and reacted at room temperature for 2 hours. After the reaction was completed as monitored by LC-MS, intermediate STAT6-10-007 was obtained by direct concentration under reduced pressure.
[0210] Synthesis of intermediate STAT6-10-008 (10.8)
[0211] Intermediate STAT6-10-007 (1.0 eq), p-toluenesulfonic acid (p-TSOH) (0.01 eq), and Shvo's catalyst (0.05 eq) were added to toluene, purged three times with nitrogen, and then the mixture was heated to 110 °C and reacted for 24 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed twice with water, and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, followed by column chromatography to obtain intermediate STAT6-10-008.
[0212] Synthesis of Compound 10 (10.9)
[0213] Intermediate STAT6-10-008 (1.0 eq) and 3-amino-2-fluorobenzamide (2.0 eq) were added to Tol, and trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60 °C for 24 hours. After the reaction was completed by LC-MS monitoring, the reaction solution was quenched with water, filtered, and the resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 10.
[0214] Example 11: Synthesis of Compound 11
[0215] Intermediate STAT6-2-009 (prepared in Example 2, 1.0 eq) and 3-amino-N-(1-cyclopropyl-1H-pyrazole-3-yl)benzamide (2.0 eq) were added to Tol. Trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60°C for 24 hours. After the reaction was completed as monitored by LC-MS, the reaction solution was quenched with water, filtered, and the resulting organic phase was concentrated under reduced pressure. Compound 11 was then prepared by reverse phase reaction.
[0216] Example 12: Synthesis of Compound 12
[0217] 12.1 Synthesis of intermediate STAT6-12-001
[0218] Intermediate STAT6-10-007 (prepared in Example 10, 1.0 eq) was dissolved in N,N-dimethylformamide, and Cs₂CO₃ (2.0 eq) and diiodomethane (3.0 eq) were added. The reaction was carried out at room temperature for 2 hours. After the reaction was monitored by LC-MS, the reaction solution was diluted with ethyl acetate, washed twice with water and once with brine. The resulting organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Then, it was subjected to column chromatography to obtain intermediate STAT6-12-001.
[0219] 12.2 Synthesis of Compound 12
[0220] Intermediate STAT6-12-001 (1.0 eq) and 3-amino-2-fluorobenzamide (2.0 eq) were added to Tol, and trimethylaluminum (3.0 eq) was slowly added dropwise under ice bath conditions. The mixture was purged with nitrogen three times, and then the temperature was raised to 60 °C for 24 hours. After the reaction was completed by LC-MS monitoring, the reaction solution was quenched with water, filtered, and the resulting organic phase was concentrated under reduced pressure and then reversed to prepare compound 12.
[0221] Bioactivity test examples
[0222] Example 1: Determination of compound activity using STAT6 fluorescence polarization (FP) method
[0223] 1. Experimental Methods
[0224] First, recombinant STAT6 protein (W123-T658) (purchased from MCE: HY-P702835A) was mixed with FAM fluorescently labeled IL-4Rα phosphorylated peptide (5-FAM-ApYKPFQDLI-NH2). The final concentrations of STAT6 and peptide were set to 450 nM and 20 nM, respectively. The test reaction solution consisted of 10 mM HEPES pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween 20, and 2 mM DTT. The compounds from the examples were prepared to the desired final concentration of 100X and then serially diluted 3X to prepare 10 compound concentrations. Add 100 μL of protein-peptide mixture to a 96-well black plate, then add 1 μL of serially diluted compound (ensuring DMSO content is 1%), vortex to mix, centrifuge (200g, 1 min), and react at room temperature in the dark for 45 min. Read the fluorescence polarization value on an MD microplate reader (excitation wavelength: 485 nm, emission wavelength: 535 nm). The fluorescence polarization values are calculated as follows: (A) without the compound of the examples, with the addition of STAT6 and peptide; (B) without the compound of the examples and with only peptide; and (C) with the addition of each compound of the examples, STAT6, and peptide. The inhibition rate of each compound is calculated using the following formula. A nonlinear analysis method is used to calculate the IC50 of each compound. 50 Inhibition rate (%) = [(AC) / (AB)] * 100
[0225] 2. Experimental Results
[0226] The experimental results are shown in the table below.
[0227] Table 2. Biochemical activities of the compounds
[0228] Example 2: Assay of STAT6-dependent reporter activity
[0229] 1. Experimental Methods
[0230] The HEK293-STAT6-Luciferase stable cell line used in the test was purchased from Genscript Biotech. HEK293-STAT6-Luciferase cells were first seeded into 96-well plates, 50 mL per well, with a cell density of 3 x 10⁶ cells / well. 4 / well, incubate overnight in a CO2 incubator (37℃, 5% CO2), while simultaneously setting up wells without cell inoculation but with the appropriate culture medium added. Add 20 mL of serially diluted compound for 1 h to ensure the final DMSO concentration is 0.1%. Add 10 mL of 80 ng / mL IL-4 solution to each well and incubate in a CO2 incubator for 6 h.
[0231] Cell viability was determined using the CellTiter-Flour kit. 20 mL of diluted CellTiter-Flour reagent was added to each well, and the cells were incubated in a CO2 incubator for 1 h. Fluorescence values were measured (excitation wavelength: 340 nm, emission wavelength: 495 nm). Cell viability was calculated using the following formula: fluorescence values without the added compounds and treated with IL-4 (D), fluorescence values without cell lines (E), and fluorescence values treated with the compounds and stimulated with IL-4 (F). Cell viability must be maintained above 70% under all test conditions.
[0232] viable cell percentage (%) = [(FE) / (DE)] * 100
[0233] STAT6 luciferase reporter activity was detected using a Bright-Glo luciferase assay system (Promega). 100 mL of reagent was added to each well, and the luciferase activity value was read on a microplate reader. Using the luciferase activity value (G) without the added compound and treated with IL-4, the luciferase activity value (H) without the added compound and without IL-4 stimulation, and the fluorescence values (I) of each compound treatment and IL-4 stimulation, the inhibition rate of each compound was calculated using the following formula. A four-parameter nonlinear analysis method was used to fit the IC50 values of each compound. 50 Inhibition rate (%) = [(GI) / (GH)] * 100
[0234] 2. Experimental Results
[0235] The experimental results are shown in the table below.
[0236] Table 3 shows the intracellular inhibition of STAT6 reporter gene activity by the compounds.
[0237] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
[0238] The foregoing embodiments and methods described in this invention may vary based on the capabilities, experience, and preferences of those skilled in the art.
[0239] Listing the steps of the method in a certain order in this invention does not constitute any restriction on the order of the method steps.
Claims
1. A compound or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, or solvate thereof, said compound having the following structure: in, X1 is selected from: N, CR4; X2 is selected from: N, CR5; X3 is selected from: N, CR6; Y1 is selected from: N, CR7; Y2 is selected from: N, CR8; Y3 is selected from: N, CR9; R4 to R9 are independently selected from: H, D, halogen, cyano, nitro, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 heterocyclic), -OR a -NR a R b -NHC(O)-R a -C(O)NR a R b -C(O)OR a -C(O)-R a -S(O)2-R a -S(O)2-NR a R b ;R a R b Independently selected from: H, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen in the aryl or 4-10 membered heterocyclic group is optionally substituted by one or more groups selected from the following: =O, halogen, cyano, hydroxyl, amino, C1-C 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 alkyl); R1 is selected from: 5-6 membered heterocyclic groups, -N(C0-C) 10 Alkyl)C(O)-R 101 -C(O)NR 101 R 102 -P(O)OR 101 OR 102 -CH2P(O)OR 101 OR 102 Among them, R 101 and R 102 Independently selected from: H, D, C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl, -(C0-C6 alkylene)-(C3-C 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen in the aryl or 4-10 membered heterocyclic group is optionally substituted by one or more groups selected from the following: =O, halogen, cyano, hydroxyl, amino, C1-C 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl; the H on the 5-6 membered heterocyclic group is optionally substituted by one or more groups selected from: D, =O, halogen, cyano, hydroxyl, amino, C1-C 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 alkyl); Ring A is a 5-7 membered heterocyclic ring; R2 is one or more independent substituents on ring A, each R2 being independently selected from: H, D, =O, halogen, cyano, nitro, hydroxyl, amino, C1-C. 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 heterocyclic), -OR 201 -N(C0-C 10 Alkyl)(R 201 -NHC(O)-R 201 -C(O)N(C0-C 10 Alkyl)(R 201 -C(O)OR 201 -C(O)-R 201 -S(O)2-R 201 -S(O)2-N(C0-C 10 Alkyl)(R 201 ); R 201 Selected from: H, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen atoms in the aryl or 4-10 membered heterocyclic groups are optionally substituted by one or more groups selected from the following: D, halogen, cyano, hydroxyl, amino, C1-C. 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 alkyl); R 10 Selected from: H, D, =O, halogen, cyano, nitro, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 heterocyclic), -OR 1001 -NR 1001 R 1002 -NHC(O)-R 1001 -C(O)NR 1001 R 1002 -C(O)OR 1001 -C(O)-R 1001 -S(O)2-R 1001 -S(O)2-NR 1001 R 1002 ;R 1001 R 1002 Independently selected from: H, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen in the aryl or 4-10 membered heterocyclic group is optionally substituted by one or more groups selected from the following: =O, halogen, cyano, hydroxyl, amino, C1-C 10 Alkyl, C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 alkyl); Z2 is selected from: N, CR 11 ;R 11 Selected from: H, D, halogen, cyano, nitro, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), wherein the C1-C 10 Alkyl, C3-C 10 The H in the cycloalkyl group is optionally substituted by one or more groups selected from the following: D, halogen, hydroxyl, amino; Or, R 10 R 11 Together with the atoms to which it is attached, it forms a heterocycle; the H in the heterocycle is optionally substituted by one or more groups selected from: D, =O, halogen, cyano, nitro, hydroxyl, amino, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), wherein the C1-C 10 Alkyl, C3-C 10 The H in the cycloalkyl group is optionally substituted by one or more groups selected from the following: D, halogen, hydroxyl, amino; L1 is selected from: -C(O)O-, -C(O)NR L -、-S(O)NR L -、-S(O)2NR L -、-CH2NR L -、-C(O)C(R L1 R L2 -, -OC(O)-, -NR L C(O)-、-NR L S(O)-、-NR L S(O)2-、-NR L CH2-, -C(R) L1 R L2 )C(O)-、-OC(R L1 R L2 )-、-C(R L1 R L2 O-, C2-C4 alkylene, C2-C4 haloalkylene, C2-C4 alkenylene; R L R L1 R L2 Independently selected from: H, D, halogens, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 Alkyl); wherein the C1-C 10 Alkyl, C3-C 10 The H in the cycloalkyl group is optionally substituted by one or more groups selected from the following: D, halogen, hydroxyl, amino; or, R L1 R L2 Together with the carbon atoms they are attached to, they form carbon rings or heterocycles; Ring B is C6-C 10 Aromatic rings or 4-12 membered heterocyclic rings; R3 is one or more independent substituents on ring B, each R3 being independently selected from: H, D, halogen, cyano, nitro, hydroxyl, amino, C1-C. 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 heterocyclic), -OR 301 -NR 301 R 302 -NHC(O)-R 301 -C(O)NR 301 R 302 -C(O)OR 301 -C(O)-R 301 -S(O)2-R 301 -S(O)2-NR 301 R 302 ;R 301 R 302 Independently selected from: H, C1-C 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), -(C0-C6 alkylene)-(C6-C 10 aryl), -(C0-C6 alkylene)-(4-10 membered heterocyclic); wherein the C1-C 10 Alkyl, C3-C 10 cycloalkyl, C6-C 10 The hydrogen atoms in the aryl or 4-10 membered heterocyclic groups are optionally substituted by one or more groups selected from the following: D, halogen, cyano, hydroxyl, amino, C1-C. 10 Alkyl, -(C0-C6 alkylene)-(C3-C6 alkylene) 10 cycloalkyl), C1-C 10 Haloalkyl, C1-C 10 Hydroxyl-substituted alkyl, C1-C 10 Amino-substituted alkyl, C1-C 10 Amide-substituted alkyl, C1-C 10 Alkoxy-substituted alkyl, C1-C 10 Alkylamine-substituted alkyl, 4-10 membered heterocyclic groups, -O(C0-C) 10 Alkyl), -N(C0-C) 10 Alkyl) (C0-C 10 alkyl), -NHC(O)-(C0-C 10 Alkyl), -C(O)N(C0-C) 10 Alkyl) (C0-C 10 Alkyl), -C(O)O-(C0-C 10 Alkyl), -C(O)-(C0-C) 10 Alkyl), -C(O)(C1-C 10 alkylene)-O-(C0-C 10 alkyl).
2. The compound according to claim 1, characterized in that, The compound has the following structure: Z1 is selected from: N, CR 12 ; More preferably, Z1 is N or CH; Preferably, X1 is CH, X2 is CH, and X3 is CH; or, X1 is N, X2 is CH, and X3 is CH; or, X1 is CH, X2 is N, and X3 is CH. Preferably, Y1 is CH and Y3 is CH; or, Y1 is N and Y3 is CH; or, Y1 is CH and Y3 is N. More preferably, Y2 is CR8, and R8 is selected from: H, halogen, C1-C6 alkyl, C1-C6 haloalkyl.
3. The compound according to any one of claims 1-2, characterized in that, The compound is selected from the following structures: Preferably, Some are selected from the following structure: More preferably, the compound is selected from the following structures:
4. The compound according to any one of claims 1-3, characterized in that, R1 is selected from: -N(C0-C 10 Alkyl)C(O)-R 101 -C(O)NR 101 R 102 , Among them, R 101 and R 102 Independently selected from: H, C1-C6 alkyl groups; R 103 Selected from: H, C1-C6 alkyl, C1-C6 haloalkyl; Preferably, R1 is selected from:
5. The compound according to any one of claims 1-4, characterized in that, Each R2 is independently selected from: H, =O, halogen, C1-C6 alkyl, C1-C6 haloalkyl.
6. The compound according to any one of claims 1-5, characterized in that, L1 is -C(=O)NR L -; Preferably, R L Selected from: H, C1-C6 alkyl, -(C0-C6 alkylene)-(C3-C6 cycloalkyl); More preferably, L1 is -C(=O)NH-.
7. The compound according to any one of claims 1-6, characterized in that, Some are selected from the following structure: in, R 303 Selected from: H, halogen, cyano, hydroxyl, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxy-substituted alkyl, C1-C6 alkoxy, C1-C6 alkoxy-substituted alkyl, C1-C6 amino-substituted alkyl, C1-C6 amide-substituted alkyl, -S(O)2-NR 306 R 307 -C(O)(C0-C6 alkyl), -N(R) 306 -C1-C6 amide-substituted alkyl, imidazolyl, thiazolyl, -C(O)NR 306 R 307 -NR 306 C(O)-R 307 ;R 306 R 307 Independently selected from: H, C1-C6 alkyl, -C(O)(C1-C6 alkyl), -(C0-C6 alkylene)-(C3-C6 cycloalkyl), -(C0-C6 alkylene)-(4-8 membered heterocyclic group); wherein the H in the C1-C6 alkyl, 4-8 membered heterocyclic group, imidazolyl, thiazolyl is optionally substituted by one or more groups selected from: halogen, cyano, -N(C0-C6 alkyl)(C0-C6 alkyl), -(C0-C6 alkylene)-(C3-C6 cycloalkyl), C1-C6 alkyl, C1-C6 haloalkyl, -C(O)(C1-C6 alkylene)-O-(C0-C6 alkyl); R 304 It has the definition of R3; R 305 Selected from: H, C1-C6 alkyl groups; Preferably, R 303 Selected from: -C(O)N(C0-C6 alkyl)(R 306 ), imidazole group, thiazolyl group; wherein the H in the imidazole group or thiazolyl group is optionally substituted by one or more groups selected from the following: C1-C6 alkyl group, C1-C6 haloalkyl group; More preferably, R 306 Selected from: H, C1-C6 cyanosubstituted alkyl, -C(O)(C1-C6 alkylene)-N(C0-C6 alkyl)(C0-C6 alkyl), Among them, R 13 Selected from: H, C1-C6 alkyl, C1-C6 cyanosubstituted alkyl, -(C0-C6 alkylene)-(C3-C6 cycloalkyl), -C(O)(C1-C6 alkylene)-O-(C0-C6 alkyl), R 14 Selected from: H, halogen, cyano, R 15 Selected from: H, C1-C6 alkyl, C1-C6 haloalkyl, R 16 Selected from: H, C1-C6 alkyl groups, R 17 Selected from: H, C1-C6 alkyl groups, R 18 Selected from: H, C1-C6 alkyl, -(C1-C6 alkylene)-O-(C1-C6 alkyl); More preferably, R 303 Selected from: More preferably, R 304 Selected from: H, halogens, C1-C6 alkyl groups, and C1-C6 haloalkyl groups; More preferably, Some are selected from the following structure:
8. The compound according to claim 1, characterized in that, The compound is selected from the following structures:
9. A pharmaceutical composition comprising the compound of any one of claims 1-8 or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate thereof, and one or more pharmaceutically acceptable excipients; Preferably, the pharmaceutical composition is an oral formulation.
10. The use of the compound of any one of claims 1-8 or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, or solvate thereof in the preparation of a medicament for the prevention and / or treatment of STAT6-related diseases; Preferably, the disease is selected from: autoimmune diseases, inflammatory diseases, allergic diseases, tumors, and fibrotic diseases; More preferably, the autoimmune disease is selected from one or more of the following: systemic lupus erythematosus, systemic vasculitis, ulcerative colitis, Crohn's disease, multiple sclerosis, and rheumatoid arthritis; and / or, The inflammatory diseases and allergic diseases mentioned are selected from: chronic obstructive pulmonary disease, atopic dermatitis, asthma, bullous pemphigoid, nasal polyps, chronic sinusitis, allergic rhinitis, eosinophilic esophagitis, prurigo, urticaria; and / or, The tumor is selected from: solitary fibroadenoma, breast cancer, prostate cancer, colon cancer, lung cancer (such as non-small cell lung cancer), gastric cancer, hepatocellular carcinoma, melanoma, malignant lymphoma; and / or, The fibrotic diseases mentioned are selected from: pulmonary fibrosis, renal fibrosis, and cutaneous fibrosis. More preferably, the disease is a lung disease, preferably from: pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, acute lung injury, and acute lung inflammation.
